{"entity":{"id":"crossbow-therapeutics","kind":"company","name":"Crossbow Therapeutics","aka":[],"tldr":"Crossbow Therapeutics makes antibody medicines that recognise fragments of proteins from inside cancer cells and pull the immune system's T cells onto them. Its first medicine is being tested in leukaemias and related blood cancers.","summary":"Crossbow Therapeutics, Inc., based in Cambridge, Massachusetts, develops T-cell receptor mimetic (TCRm) antibodies that bind tumour peptides presented on HLA, built into T-cell engagers it calls T-Bolt molecules. It was founded, seeded and incubated at MPM BioImpact. The lead programme CBX-250 targets a cathepsin G peptide presented by HLA-A*02:01 and is in the CROSSCHECK-001 phase 1 trial (NCT06994676) in relapsed or refractory AML, higher-risk MDS, CMML and CML, given under the skin; the company dosed its first patient in September 2025. A second programme, CBX-663, targets a TERT-derived peptide on HLA-A*02:01 and entered a phase 1 trial (NCT07779798) in myeloid malignancies, advanced solid tumours and recurrent glioblastoma, with a first patient dosed in September 2026. The company launched in July 2023 with an 80 million US dollar Series A led by MPM BioImpact and Pfizer Ventures, and raised a 77 million US dollar Series B in March 2026 co-led by Taiho Ventures and Arkin Bio Capital. Its first registered cancer trial, NCT06994676, was posted on ClinicalTrials.gov in May 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.crossbowtx.com/"},{"label":"Series B release, March 2026","url":"https://www.crossbowtx.com/press-release-03-18-26"},{"label":"Launch and Series A release, July 2023","url":"https://www.crossbowtx.com/press-release-7-11-23"},{"label":"ClinicalTrials.gov: CROSSCHECK-001 phase 1 trial of CBX-250 (NCT06994676)","url":"https://clinicaltrials.gov/study/NCT06994676"},{"label":"ClinicalTrials.gov: phase 1 trial of CBX-663 (NCT07779798)","url":"https://clinicaltrials.gov/study/NCT07779798"}],"tags":[],"related":[],"cancers":["aml","mds-higher-risk","cmml","cml","glioblastoma"],"sections":["immunotherapy"],"technologies":["t-cell-engager"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website; the July 2023 launch release says the company was founded, seeded and incubated at MPM BioImpact. Releases read on 29 October 2026.","No clinical results have been read; the company expected initial CROSSCHECK-001 data around the end of 2026."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.crossbowtx.com/","stage":"growth","investors":["mpm-bioimpact","pfizer-ventures","polaris-partners"],"funding":[{"round":"Series A","year":2023,"amountUsd":80000000,"source":"https://www.crossbowtx.com/press-release-7-11-23","note":"Led by MPM BioImpact and Pfizer Ventures, with Polaris Partners, BVF Partners, Eli Lilly and Company and Mirae Asset"},{"round":"Series B","year":2026,"amountUsd":77000000,"source":"https://www.crossbowtx.com/press-release-03-18-26","note":"Co-led by Taiho Ventures and Arkin Bio Capital"}]},"route":"/companies/crossbow-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"company":[{"id":"mpm-bioimpact","kind":"company","name":"MPM BioImpact","route":"/companies/mpm-bioimpact/"},{"id":"pfizer-ventures","kind":"company","name":"Pfizer Ventures","route":"/companies/pfizer-ventures/"},{"id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/"}]}}